6 Einträge gefunden

1. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

   1. Reich, K
   2. Blauvelt, A
   3. Armstrong, A
   4. Langley, R G
   5. de Vera, A
   6. Kolbinger, F
   7. Spindeldreher, S

   2019 - Forschungsinformationssystem des UKE
2. Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis

   1. Lebwohl, M
   2. Langley, R G
   3. Zhu, Y
   4. Zhou, H
   5. Song, M
   6. Shen, Y K
   7. Parnell Lafferty, K

   2019 - Forschungsinformationssystem des UKE
3. Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice

   1. Maul, J-T
   2. Navarini, A A
   3. Sommer, R
   4. Anzengruber, F
   5. Sorbe, C
   6. Mrowietz, U
   7. Drach, M

   2019 - Forschungsinformationssystem des UKE
4. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing Spondylitis: integrated pooled clinical trial and post-marketing surveillance data

   1. Deodhar, A
   2. Mease, P J
   3. McInnes, I B
   4. Baraliakos, X
   5. Reich, K
   6. Blauvelt, A
   7. Leonardi, C

   2019 - Forschungsinformationssystem des UKE - frei zugänglich
5. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients

   1. Augustin, M
   2. Sommer, R
   3. Kirsten, N
   4. Danckworth, A
   5. Radtke, M A
   6. Reich, K
   7. Thaci, D

   2019 - Forschungsinformationssystem des UKE
6. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials

   1. Blauvelt, A
   2. Sofen, H
   3. Papp, K
   4. Gooderham, M
   5. Tyring, S
   6. Zhao, Y
   7. Lowry, S

   2019 - Forschungsinformationssystem des UKE